EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients

MLA

Bossé, Y., et al. “EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients.” Journal of Thoracic Oncology, vol. 17, no. 9, Number 9 Supplement 1, Sept. 2022, p. S583. EBSCOhost, https://doi.org/10.1016/j.jtho.2022.07.1058.

APA

Bossé, Y., Abbosh, C., Abadier, M., Gupta, A. D., Armero, V. S., Gaudreault, N., Orain, M., Lamaze, F., Tom, J., Melton, C., Hung, T., Hodgson, D., & Joubert, P. (2022). EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients. Journal of Thoracic Oncology, 17(9, Number 9 Supplement 1), S583. https://doi.org/10.1016/j.jtho.2022.07.1058

Chicago

Bossé, Y., C. Abbosh, M. Abadier, A. Das Gupta, V. Saavedra Armero, N. Gaudreault, M. Orain, et al. 2022. “EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients.” Journal of Thoracic Oncology 17 (9, Number 9 Supplement 1): S583. doi:10.1016/j.jtho.2022.07.1058.